Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 398,980 |
|
|||||
| News | - | ||||||
| Day High | 2.34 | Low High |
|||||
| Day Low | 2.2075 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BioAtla Inc | BCAB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.10 | -4.26% | 2.25 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.32 | 2.2075 | 2.34 | 2.25 | 2.35 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,724 | 398,980 | $ 2.26 | $ 903,122 | - | 1.24 - 4.068 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:31:00 | 1 | $ 2.31 | USD |
BioAtla Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 107.86M | 47.94M | - | 0 | -123.46M | -2.58 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
BioAtla News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCAB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.54 | 2.56 | 2.005 | 2.22 | 619,115 | -0.29 | -11.42% |
| 1 Month | 3.50 | 4.02 | 2.005 | 3.17 | 696,748 | -1.25 | -35.71% |
| 3 Months | 1.91 | 4.02 | 1.77 | 2.89 | 562,030 | 0.34 | 17.80% |
| 6 Months | 1.34 | 4.02 | 1.24 | 2.40 | 518,077 | 0.91 | 67.91% |
| 1 Year | 3.41 | 4.068 | 1.24 | 2.60 | 430,140 | -1.16 | -34.02% |
| 3 Years | 50.98 | 57.46 | 1.24 | 7.91 | 514,251 | -48.73 | -95.59% |
| 5 Years | 30.55 | 76.63 | 1.24 | 10.47 | 489,639 | -28.30 | -92.64% |
BioAtla Description
| BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs. |
